中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(11): 2351-2358

The mechanism of Dange Jiecheng decoction improving alcoholic liver disease in a rat model

DOI: 10.12449/JCH251123
  • 1.

    School of Traditional Chinese Medicine，Ningxia Medical University，Yinchuan 750004，China

  • 2.

    Key Laboratory of Modernization of Ethnic Minority Medicine，Ministry of Education，Yinchuan 750004，China

Research funding:

Ningxia Natural Science Foundation (2023AAC03210);

Construction Project of High-Level Key Disciplines in Traditional Chinese Medicine by the National Administration of Traditional Chinese Medicine (zyyzdxk-2023209);

2022 National Famous Old Chinese Medicine Experts Inheritance Workstation Construction Project（Guo Zhongyiyao Renjiao Han ［2022］ No. 75） 

More Information
  • Corresponding author: MA Li， mali3549@163.com （ORCID： 0000-0002-6646-3484）
  • Received Date: 2025-06-12
  • Accepted Date: 2025-08-12
  • Published Date: 2025-11-25
    Abstract
  •   Objective  To investigate the effect of Dange Jiecheng decoction in improving alcoholic liver disease （ALD） in rats， as well as its mechanism of action based on the tumor protein P53/glutathione peroxidase 4 （GPX4） signaling pathway.  Methods  A total of 36 male Sprague-Dawley rats were randomly divided into normal group， model group， Dange Jiecheng decoction group， and compound Yiganling tablets group， with 9 rats in each group. The rats were given gradient intragastric administration of 56% alcohol to establish a model of ALD， and meanwhile， the corresponding drug was given by gavage for 12 consecutive weeks. After the experiment ended， serum and liver tissue samples were collected to measure the serum levels of alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， and triglyceride （TG） and the levels of malondialdehyde （MDA）， reactive oxygen species （ROS）， glutathione （GSH）， and Fe2+； HE staining was used to observe histopathological changes， and oil red O staining and Prussian blue staining were used to observe fat and iron deposition in liver tissue， respectively； RT-qPCR and Western blot were used to measure the mRNA and protein expression levels of P53， glutathione peroxidase 4 （GPX4）， NADPH oxidase 1 （NOX1）， prostaglandin-endoperoxide synthase 2 （PTGS2）， and ferritin heavy chain 1 （FTH1） in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  Compared with the normal group， the model group had disordered arrangement and incomplete structure of hepatocytes with inflammatory cell infiltration and a large number of fat vacuoles， significant increases in the serum levels of AST， ALT， TG and the levels or activities of MDA， ROS， and Fe2+ in liver tissue （all P<0.01）， significant increases in the mRNA and protein expression levels of P53， NOX1， and PTGS2 （all P<0.01）， and significant reductions in the content of GSH in serum and the mRNA and protein expression levels of GPX4 and FTH1 in liver tissue （all P<0.01）. Compared with the model group， the Dange Jiecheng decoction group and the compound Yiganling tablets group had ordered arrangement of hepatocytes with a reduction in inflammation， significant reductions in the serum levels of AST， ALT， and TG， the levels of MDA， ROS， and Fe2+ in liver tissue， and the mRNA and protein expression levels of P53， NOX1， and PTGS2 in liver tissue （all P<0.05）， and significant increases in the content of GSH in serum and the mRNA and protein expression levels of GPX4 and FTH1 in liver tissue （all P<0.05）， as well as an improvement in hepatic steatosis and a reduction in iron deposition （all P<0.01）.  Conclusion  Dange Jiecheng decoction can effectively improve disease progression in rats with ALD， possibly by regulating the P53/GPX4 pathway and inhibiting ferroptosis.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    WANG Q, ZHANG CR, TANG YM. Research advances in glucose and lipid metabolism disorders in different types of chronic liver diseases[J]. J Clin Hepatol, 2022, 38( 8): 1937- 1940. DOI: 10.3969/j.issn.1001-5256.2022.08.043.

    王倩, 张宸瑞, 唐映梅. 不同类型慢性肝病糖脂代谢紊乱研究进展[J]. 临床肝胆病杂志, 2022, 38( 8): 1937- 1940. DOI: 10.3969/j.issn.1001-5256.2022.08.043.
    [2]
    REHM J, SAMOKHVALOV AV, SHIELD KD. Global burden of alcoholic liver diseases[J]. J Hepatol, 2013, 59( 1): 160- 168. DOI: 10.1016/j.jhep.2013.03.007.
    [3]
    GAO XX, LIU LX. Progress in the epidemiology and pathogenesis of alcoholic liver diseases[J/OL]. Chin J Digest Med Imageol: Electronic Edition, 2016, 6( 2): 62- 65. DOI: 10.3877/cma.j.issn.2095-2015.2016.02.004.

    高潇雪, 刘立新. 酒精性肝病流行病学及发病机制研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2016, 6( 2): 62- 65. DOI: 10.3877/cma.j.issn.2095-2015.2016.02.004.
    [4]
    DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
    [5]
    JIANG XJ, STOCKWELL BR, CONRAD M. Ferroptosis: Mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22( 4): 266- 282. DOI: 10.1038/s41580-020-00324-8.
    [6]
    LI X, TAO L, ZHONG MJ, et al. Ferroptosis and liver diseases[J]. J Zhejiang Univ Med Sci, 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566.

    李欣, 陶亮, 钟美娟, 等. 铁死亡参与肝疾病研究进展[J]. 浙江大学学报(医学版), 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566.
    [7]
    MA YD, HU XY, KE R. Research progress on treatment of alcoholic liver disease based on ferroptosis mechanism of traditional Chinese medicine[J]. J Liaoning Univ Tradit Chin Med, 2024, 26( 11): 148- 153. DOI: 10.13194/j.issn.1673-842X.2024.11.029.

    马伊笛, 胡晓阳, 客蕊. 中药经铁死亡途径治疗酒精性肝病研究进展[J]. 辽宁中医药大学学报, 2024, 26( 11): 148- 153. DOI: 10.13194/j.issn.1673-842X.2024.11.029.
    [8]
    CHEN X, KANG R, KROEMER G, et al. Broadening horizons: The role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18( 5): 280- 296. DOI: 10.1038/s41571-020-00462-0.
    [9]
    SEIBT TM, PRONETH B, CONRAD M. Role of GPX4 in ferroptosis and its pharmacological implication[J]. Free Radic Biol Med, 2019, 133: 144- 152. DOI: 10.1016/j.freeradbiomed.2018.09.014.
    [10]
    JU Z, ZHANG R, YANG AG, et al. Mutant p53 promotes iron death of human colon and lung cancer cells by down-regulating glutathione peroxidase 4(GPX4) expression and increasing the production of lipid reactive oxygen species[J]. Chin J Cell Mol Immunol, 2022, 38( 6): 522- 527. DOI: 10.13423/j.cnki.cjcmi.009378.

    雎转, 张瑞, 杨安钢, 等. 突变型p53通过下调谷胱甘肽过氧化物酶4(GPX4)表达和增加脂质活性氧产生促进人结肠癌和肺癌细胞的铁死亡[J]. 细胞与分子免疫学杂志, 2022, 38( 6): 522- 527. DOI: 10.13423/j.cnki.cjcmi.009378.
    [11]
    CHEN C, HUANG Y, XIA PP, et al. Long noncoding RNA Meg3 mediates ferroptosis induced by oxygen and glucose deprivation combined with hyperglycemia in rat brain microvascular endothelial cells, through modulating the p53/GPX4 axis[J]. Eur J Histochem, 2021, 65( 3): 3224. DOI: 10.4081/ejh.2021.3224.
    [12]
    WANG M, MA L. Study on the mechanism of Dange Jiecheng Decoction on alcoholic liver disease based on network pharmacology and experimental verification[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 8): 716- 722. DOI: 10.3969/j.issn.1005-0264.2023.008.009.

    王铭, 马丽. 基于网络药理学与实验验证的丹葛解酲汤干预酒精性肝病机制研究[J]. 中西医结合肝病杂志, 2023, 33( 8): 716- 722. DOI: 10.3969/j.issn.1005-0264.2023.008.009.
    [13]
    WANG M, XU JH, MA L. Mechanism of action of Dange Jiecheng decoction in a rat model of alcoholic liver disease based on the Kelch-like ECH-associated protein1/nuclear factor erythroid 2-related factor 2 signaling pathway[J]. J Clin Hepatol, 2023, 39( 5): 1119- 1125. DOI: 10.3969/j.issn.1001-5256.2023.05.018.

    王铭, 徐建虎, 马丽. 基于Keap1/Nrf2信号通路探讨丹葛解酲汤对酒精性肝病大鼠模型的作用机制[J]. 临床肝胆病杂志, 2023, 39( 5): 1119- 1125. DOI: 10.3969/j.issn.1001-5256.2023.05.018.
    [14]
    QI LMG, ZHANG J, DUAN HJ, et al. Comparison and evaluation of methods for establishing animal models of alcoholic liver disease[J]. Pharmacol Clin Chin Mater Med, 2022, 38( 5): 153- 161. DOI: 10.13412/j.cnki.zyyl.20220627.001.

    其乐木格, 张娟, 段海婧, 等. 酒精性肝病动物模型建立方法的比较与评价[J]. 中药药理与临床, 2022, 38( 5): 153- 161. DOI: 10.13412/j.cnki.zyyl.20220627.001.
    [15]
    YUAN HS, PRATTE J, GIARDINA C. Ferroptosis and its potential as a therapeutic target[J]. Biochem Pharmacol, 2021, 186: 114486. DOI: 10.1016/j.bcp.2021.114486.
    [16]
    SUN YT, CHEN P, ZHAI BT, et al. The emerging role of ferroptosis in inflammation[J]. Biomed Pharmacother, 2020, 127: 110108. DOI: 10.1016/j.biopha.2020.110108.
    [17]
    ZHUANG JL, RUAN FH, QIAN TM, et al. Ferroptosis and metabolic syndrome: From basic mechanism to therapeutic strategy[J]. Chin J Evid Based Cardiovasc Med, 2025, 17( 2): 246- 251. DOI: 10.3969/j.issn.1674-4055.2025.02.23.

    庄金龙, 阮发晖, 钱涛铭, 等. 铁死亡与代谢综合征: 从基础机制到潜在治疗策略[J]. 中国循证心血管医学杂志, 2025, 17( 2): 246- 251. DOI: 10.3969/j.issn.1674-4055.2025.02.23.
    [18]
    LIU J, KANG R, TANG DL. Signaling pathways and defense mechanisms of ferroptosis[J]. FEBS J, 2022, 289( 22): 7038- 7050. DOI: 10.1111/febs.16059.
    [19]
    URSINI F, MAIORINO M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4[J]. Free Radic Biol Med, 2020, 152: 175- 185. DOI: 10.1016/j.freeradbiomed.2020.02.027.
    [20]
    TIAN Y, LU J, HAO XQ, et al. FTH1 inhibits ferroptosis through ferritinophagy in the 6-OHDA model of Parkinson’s disease[J]. Neurotherapeutics, 2020, 17( 4): 1796- 1812. DOI: 10.1007/s13311-020-00929-z.
    [21]
    DANG YN, HE Q, YANG SY, et al. FTH1- and SAT1-induced astrocytic ferroptosis is involved in Alzheimer’s disease: Evidence from single-cell transcriptomic analysis[J]. Pharmaceuticals(Basel), 2022, 15( 10): 1177. DOI: 10.3390/ph15101177.
    [22]
    XU R, WANG WN, ZHANG WL. Ferroptosis and the bidirectional regulatory factor p53[J]. Cell Death Discov, 2023, 9( 1): 197. DOI: 10.1038/s41420-023-01517-8.
    [23]
    ZHANG W, LIU Y, LIAO Y, et al. GPX4, ferroptosis, and diseases[J]. Biomed Pharmacother, 2024, 174: 116512. DOI: 10.1016/j.biopha.2024.116512.
    [24]
    ZHANG ZL, LIN XY, WANG WR, et al. Effect of modified Shaofu Zhuyutang on ferroptosis in ectopic endometrial tissues of rats with endometriosis based on MDM4/p53/GPX4 signaling pathway[J]. Chin J Exp Tradit Med Formulae, 2025, 31( 4): 39- 47. DOI: 10.13422/j.cnki.syfjx.20242245.

    张作良, 林祥羽, 王婉润, 等. 基于MDM4/p53/GPX4信号通路探讨加味少腹逐瘀汤对子宫内膜异位症大鼠异位子宫内膜组织铁死亡的影响[J]. 中国实验方剂学杂志, 2025, 31( 4): 39- 47. DOI: 10.13422/j.cnki.syfjx.20242245.
    [25]
    ZHANG JH, HUO H, XU RQ, et al. Effect of MDM2 on ferroptosis in colon cancer cells through the P53/GPX4 pathway[J/OL]. J Yunnan Minzu Univ Nat Sci Ed, 2025.[ Epub ahead of print]

    张金华, 霍虹, 许瑞琪, 等. MDM2通过P53/GPX4通路对结肠癌细胞铁死亡的影响[J/OL]. 云南民族大学学报(自然科学版), 2025.[网络首发]
    [26]
    GONG W, WANG Y, LI Q, et al. Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia[J]. Front Mol Biosci, 2025, 12: 1557218. DOI: 10.3389/fmolb.2025.1557218.
    [27]
    YU XY, WU WW, HAO JJ, et al. Ginger protects against vein graft remodeling by precisely modulating ferroptotic stress in vascular smooth muscle cell dedifferentiation[J]. J Pharm Anal, 2025, 15( 2): 101053. DOI: 10.1016/j.jpha.2024.101053.
    [28]
    ZHOU YQ, ZHOU HX, HUA L, et al. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis[J]. Free Radic Biol Med, 2021, 171: 55- 68. DOI: 10.1016/j.freeradbiomed.2021.05.009.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (5) PDF downloads(3) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return